Immune
AC Immune Reports Promising Phase 2 Interim Data for Parkinson’s Immunotherapy ACI-7104.056
AC Immune; ACI-7104.056; Parkinson’s disease; Phase 2 trial; alpha-synuclein; biomarker stabilization
AC Immune Narrows Pipeline and Cuts 30% Workforce to Extend Cash Runway
AC Immune; pipeline reduction; layoffs; cash runway; biotech; Alzheimer’s disease; Parkinson’s disease; late-stage assets; workforce reduction
AltruBio Secures $225 Million for Phase II Trials of Novel Immune Checkpoint Enhancing Antibody
AltruBio, funding, Phase II trials, immune checkpoint enhancing antibody, cancer treatment, immunotherapy, biotechnology, healthcare innovation.